Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLR 1404 I-131

Drug Profile

CLR 1404 I-131

Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 131; CLR1404-I-131; HOT; I-131-CLR1404; NM-404

Latest Information Update: 07 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Antineoplastics; Drug conjugates; Phospholipid ethers; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma; Rhabdomyosarcoma; Neuroblastoma; Multiple myeloma; Osteosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Multiple myeloma
  • Phase I/II Non-small cell lung cancer
  • Phase I Lymphoma; Neuroblastoma; Solid tumours
  • Preclinical Head and neck cancer

Most Recent Events

  • 30 Sep 2019 Updated efficacy and safety data from the phase II CLOVER-1 trial in Haematological malignancies released by Cellectar Biosciences
  • 24 Sep 2019 CLR 1404 I-131 receives Orphan Drug status for Multiple myeloma in Europe
  • 16 Sep 2019 Updated efficacy and adverse events data from a phase Ib trial in Multiple myeloma (Second-line therapy or greater) released by Cellectar Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top